Optimize Your Health - Available Everywhere in the US

  188-8981-6784    HIPAA Compliant  ·  Licensed U.S. Providers

LL-37

LL-37 — Human Cathelicidin for Antimicrobial and Wound Biology Research. Physician-Supervised

LL-37 is the only known human cathelicidin — a naturally occurring antimicrobial peptide produced by neutrophils, epithelial cells, and other immune cells as part of the body’s first-line defence against infection. Beyond antimicrobial activity, it has been studied for its role in wound healing biology, including keratinocyte migration, angiogenesis, and immune modulation. It is available at OptiMale USA following clinical assessment.

WHAT IS IT?

Understanding LL-37

LL-37 is produced from the human cathelicidin precursor protein hCAP-18. It is a 37 amino acid cationic peptide that disrupts bacterial cell membranes through electrostatic interaction — a mechanism that makes it effective against a broad spectrum of bacteria, fungi, and even some viruses in research settings. Beyond its antimicrobial function, LL-37 also acts as a signalling molecule that stimulates skin cells (keratinocytes) to migrate and proliferate, promotes angiogenesis, and modulates inflammatory signalling in wound tissue.
Research has examined LL-37 in wound healing biology — particularly in skin and mucosal tissue — for its combined antimicrobial and repair-promoting properties. It has also been studied in the context of chronic wound management, biofilm disruption, and immune signalling. At OptiMale USA, LL-37 is discussed for men with specific wound healing or skin tissue biology goals following thorough assessment. Administration is typically topical for skin applications or subcutaneous injection for deeper tissue contexts.

LL 37
Quick Facts

Injection

Timeline: Immune support effects within 1–2 weeks; wound healing and infection management over 4–8 weeks
Lab required: Yes
Ongoing maintenance: Protocol-dependent
Pricing:  Contact for Pricing

Related Treatments

Benefits

Broad-spectrum antimicrobial research

LL-37 disrupts bacterial cell membranes through a mechanism different from conventional antibiotics — targeting membrane integrity rather than specific bacterial metabolic processes. Research has studied this activity across a wide range of bacterial species and also examined antifungal and antiviral properties in preclinical models.

Keratinocyte migration and skin repair research

Beyond antimicrobial activity, LL-37 has been studied for its effects on keratinocyte — skin cell — migration and proliferation. Research has examined this in wound closure biology, investigating how LL-37 stimulates the movement of skin cells to cover wound surfaces.

Wound angiogenesis research

LL-37 has been investigated for its ability to promote new blood vessel formation in wound tissue — an important step in wound healing that restores oxygen and nutrient delivery to repair cells. This angiogenic activity has been studied alongside its keratinocyte effects in wound biology research.

Immune modulation in wound context

Research has examined LL-37's role in modulating inflammatory signalling in wound tissue — both recruiting relevant immune cells to the site and helping regulate the inflammatory response as repair progresses. This dual role as antimicrobial agent and immune modulator is a distinctive characteristic of LL-37's research profile.

Who Is This For?

Am I a Good Candidate?

Ideal For

  • Men with wound healing concerns or chronic skin tissue issues who have been assessed by a licensed provider
  • Men with susceptibility to skin infection or compromised wound healing in the context of their broader health profile
  • Men whose clinical assessment identifies specific skin or mucosal tissue biology as a relevant focus
  • Men who have completed a full assessment at OptiMale USA and for whom LL-37 is clinically discussed

Not Recommended If

  • Men with active malignancy — LL-37’s cell proliferation effects are a consideration with cancer
  • Men with autoimmune skin conditions that could be exacerbated by immune modulation
  • Men who have not been assessed by a licensed OptiMale USA provider
  • Men under 18
Safety

Potential Side Effects

LL-37 is endogenously produced by the human body, which contributes to its tolerability profile. Exogenous administration is less well characterised in formal human trials. All OptiMale USA patients are monitored throughout with clinical check-ins.

Common Questions

Frequently Asked Questions

Get started

Discuss LL-37 With a Provider

Your free consultation is the first step. A licensed OptiMale USA provider will review your bloodwork, health history, and goals before making any recommendations.

These statements have not been evaluated by the Food and Drug Administration. The information on this website is provided for educational and informational purposes only and does not constitute medical advice, a diagnosis, a treatment recommendation, or an offer to prescribe, supply, compound, administer, or dispense any product.

Compounded medications. Compounded medications, including compounded semaglutide and compounded tirzepatide, are not FDA-approved and are not generic equivalents of brand-name products such as Ozempic®, Wegovy®, Mounjaro®, or Zepbound®. The FDA does not review compounded drugs for safety, effectiveness, or quality prior to dispensing. Compounded medications are prepared by state-licensed 503A compounding pharmacies or FDA-registered 503B outsourcing facilities pursuant to a valid prescription from a licensed provider following individual patient evaluation. Availability of compounded medications varies by state and is subject to applicable state and federal law.

Research compounds. Certain compounds referenced on this website are research compounds that are not approved by the FDA for human use and have not been evaluated by the FDA for safety, efficacy, or quality. Information about these compounds is provided solely for educational and informational purposes and reflects publicly available scientific literature. OptiMale USA and its affiliated providers do not prescribe, supply, recommend, compound, administer, or dispense research compounds, and nothing on this website should be construed as an offer to do so. Patient consent forms purporting to waive provider duty of care with respect to research compounds are not recognized as a defense to professional liability and are not used by OptiMale USA.

Clinical services. All prescription products and services offered through OptiMale USA are prescribed exclusively by board-certified, licensed U.S. providers following individual clinical evaluation, comprehensive bloodwork where indicated, and a detailed health assessment. Available services and products vary by state based on provider licensure and applicable law. No provider-patient relationship is established by use of this website; a provider-patient relationship is formed only upon completion of a clinical evaluation with a licensed OptiMale USA provider.

Individual results vary. Always consult a qualified healthcare provider before beginning any new health protocol.

  • Home
  • Products
  • Solutions
  • How it Works
  • Peptide Library